Skip to main content

Menopause

Women's Health
25
Pipeline Programs
30
Companies
50
Clinical Trials
5 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
1
2
3
5
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
267%
Small Molecule
133%
+ 59 programs with unclassified modality

Women's Health is a $989M market with mature, consolidated portfolios dominated by legacy hormone therapies and specialty oncology agents.

$0.989B marketMature→ Stable30 products15 companies

Key Trends

  • Heavy concentration in estrogen receptor agonists and single-blockbuster dependency (INLYTA 47% of market)
  • Multiple patent cliffs 2027-2030 creating near-term revenue pressure and consolidation risk
  • Hiring concentrated in commercial and specialty recruitment, not R&D expansion

Career Verdict

Viable but cautious entry point—stable commercial roles available, but limited innovation pipeline and impending LOE events suggest a mature market in defensive posture rather than growth mode.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1INLYTAStable
$0.467B
Pfizer·Peak11.2yr
#2KORLYMStable
$0.229B
#3LUPRON DEPOTDeclining
$0.129B
AbbVie·LOE Approaching
#4ESTRINGDeclining
$0.050B
Pfizer·LOE Approaching
#5PREMPRODeclining
$0.040B
Pfizer·LOE Approaching

Drug Class Breakdown

Receptor Tyrosine Kinase Inhibitors
$0.467B(47%)

single-product dominance (INLYTA)

Progestational Hormone Receptor Antagonists
$0.229B(23%)

concentrated in specialty reproductive health

GnRH Analogs
$0.129B(13%)

legacy product with pending LOE pressure

Estrogen Receptor Agonists
$0.128B(13%)

fragmented across 17 products, majority LOE-approaching

Vascular Endothelial Growth Factor Antibodies
$0.012B(1%)

minor indication-specific use

Selective Estrogen Receptor Modulators
$0.005B(0.5%)

niche positioning, small market share

Career Outlook

Stable

Women's Health is a mature, consolidated market where career growth is incremental rather than exponential. Pfizer and AbbVie control ~61% of spending via blockbuster and legacy products, creating stable but competitive commercial environments. Impending patent cliffs (2027-2030) and fragmented early-stage pipeline suggest cost containment and defensive strategy dominance over expansion, meaning fewer senior advancement slots and limited innovation-driven upside. Opportunity exists in specialty segments (fertility platforms, digital health, device innovation) outside traditional pharma.

Breaking In

Target specialty commercial roles (MSL, outcomes research) or non-traditional employers (Progyny, digital health startups, device firms) rather than incumbent pharma, which offers less differentiation for new entrants.

For Experienced Professionals

Experienced professionals should assess portfolio defensibility and patent cliff timing before joining a company; AbbVie and Pfizer offer scale but entail consolidation risk, while boutique firms (Corcept, Duchesnay) offer strategic leverage in niche areas.

In-Demand Skills

Commercial execution and market access (mature market management)Digital health and telehealth integration (competitive differentiation)Regulatory affairs and post-approval strategy (LOE mitigation)Real-world evidence and outcomes research (payer pressure)Data analytics and IT (reflecting commercial IT hiring spike)

Best For

Territory/Brand Manager (Commercial)Medical Science Liaison (specialist sales)Regulatory Affairs Manager (LOE and lifecycle management)Market Access/Outcomes Research AnalystProduct Manager (digital health platforms, fertility tech)

Hiring Landscape

$43K-$222K

Women's Health hiring totals 117 jobs, but data shows significant reporting gaps (many major companies report 0 jobs despite large portfolios). Visible hiring is concentrated in Viatris (40 jobs, likely manufacturing/supply chain post-spinoff), Progyny (29 jobs, fertility/reproductive benefits platform), and specialized device/diagnostics firms (GE HealthCare, Caldera Medical, Natera). Commercial roles dominate disclosed positions (65 of 109 departmental roles), with IT second (7 roles at $222K avg, reflecting digital health emphasis).

117
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

Viatris
40Stable
29Growing
7Growing

By Department

Commercial(59%)
$82K
IT(6%)
$222K
Clinical Operations(8%)
$0K
Business Development(4%)
$145K
Finance(4%)
$43K

Commercial and specialty sales roles offer stable near-term opportunity, but modest average salary ($82K commercial) and portfolio maturity suggest limited high-growth compensation upside; IT roles offer premium but are scarce.

On Market (1)

Approved therapies currently available

Eli Lilly and Company
FORTEOApproved
teriparatide
Eli Lilly and Company
Parathyroid Hormone Analog [EPC]subcutaneous2002
425M Part D

Competitive Landscape

28 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
11 programs
1
1
3
DegarelixPhase 41 trial
GnRH antagonistPhase 41 trial
GnRH antagonistPhase 41 trial
MetforminPhase 2/31 trial
KUVANPhase 11 trial
+6 more programs
Active Trials
NCT03370991Completed43Est. Sep 2021
NCT00995631Completed53Est. Dec 2014
NCT03183102Completed30Est. Dec 2022
+8 more trials
Pfizer
PfizerNEW YORK, NY
8 programs
4
2
1
quinaprilPhase 4Small Molecule1 trial
DVS-233Phase 31 trial
bazedoxifene 20 mg/ conjugated estrogens 0.45 mgPhase 31 trial
Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tabletPhase 11 trial
Duavive 0.45Mg-20Mg TabletPhase 11 trial
+3 more programs
Active Trials
NCT06033521Completed1,036,294Est. Mar 2024
NCT00464789CompletedEst. May 2007
NCT04478305Recruiting30Est. Dec 2025
+5 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
TeriparatidePHASE_2_3Peptide
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
Estradiol vaginal ringPhase 41 trial
Active Trials
NCT03336437Completed40Est. Aug 2019
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
ParoxetinePhase 4
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
TibolonePhase 41 trial
Active Trials
NCT06117969Unknown180Est. Sep 2025
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
LNG IUSPhase 31 trial
BAY86-4891N/A1 trial
Active Trials
NCT03126773Completed1,570Est. Jun 2020
NCT00185458Completed394Est. May 2008
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
esmirtazapinePhase 3
MSD
MSDIreland - Ballydine
1 program
1
esmirtazapinePhase 31 trial
Active Trials
NCT00560833Completed943Est. Jan 2006
Prevail Therapeutics
2 programs
1
TeriparatidePhase 2/3Peptide1 trial
atomoxetineN/A1 trial
Active Trials
NCT00611533Completed16Est. Apr 2008
NCT00697463Completed22Est. Jan 2012
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Qing'E pillsPhase 2/31 trial
Active Trials
NCT01805765Completed240Est. Oct 2014
NeRRe Therapeutics
NeRRe TherapeuticsUK - Stevenage
1 program
1
ElinzanetantPhase 2
NeuTherapeutics
NeuTherapeuticsAZ - Tucson
1 program
1
PhytoSERMPhase 21 trial
Active Trials
NCT06186531Unknown132Est. Nov 2024
Young BioPharma
Young BioPharmaMA - Lowell
1 program
1
SEGOVA procedurePhase 1/21 trial
Active Trials
NCT04009473Unknown100Est. Dec 2021
Viramal
ViramalUK - London
1 program
1
EstrogelPhase 11 trial
Active Trials
NCT03556800Unknown20Est. Jun 2022
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
14 programs
0.5 mg estradiol / 0.1 mg norethisterone acetateN/A1 trial
Marketed low dose hormone replacement therapyN/A1 trial
estradiol, 25 mcgN/A1 trial
0.5 mg estradiol / 0.1 mg norethisterone acetatePHASE_11 trial
2 mg estradiol / 1 mg norethisterone acetatePHASE_11 trial
+9 more programs
Active Trials
NCT01076621Completed176Est. Jun 2013
NCT01487304Completed3,760Est. Jun 2006
NCT01507454Completed1,613Est. Nov 2006
+11 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
Recreational team handballN/A
pulsesN/A1 trial
Active Trials
NCT04692298Completed41Est. Dec 2023
Teva
TevaIsrael - Petach Tikva
2 programs
DR-2041aPHASE_31 trial
ArmodafinilPHASE_41 trial
Active Trials
NCT00361569Completed622Est. Sep 2007
NCT01460628Completed25Est. Dec 2013
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
3 caps x3/dayN/A1 trial
Active Trials
NCT04552106Completed50Est. Nov 2018
Elysium Therapeutics
1 program
BASIS™N/A1 trial
Active Trials
NCT04841499Completed40Est. Jul 2021
Otsuka
OtsukaJapan - Tokushima
1 program
Consumption of soy protein barN/A1 trial
Active Trials
NCT07136220Recruiting300Est. Dec 2025
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Egg consumptionN/A1 trial
Active Trials
NCT02679794Completed20Est. Aug 2017
Biocorp
BiocorpFrance - Issoire
1 program
L-CitrullineN/A1 trial
Active Trials
NCT04672447Completed39Est. Apr 2022
Innovation Pharmaceuticals
1 program
Recreational team handballN/A1 trial
Active Trials
NCT05292261Completed80Est. Mar 2018
Biomed
BiomedAustralia - Sydney
1 program
Shatavari extractN/A1 trial
Active Trials
NCT06716554Recruiting51Est. Jan 2025
IBSA Institut Biochimique
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
1 program
ProgesteronePHASE_21 trial
Active Trials
NCT02841137Completed80Est. Apr 2018
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Low dose of Klimadynon®PHASE_31 trial
Active Trials
NCT02184364Completed161
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
ovaria comp 10 globuli 3 times per day 24 weeksPHASE_41 trial
Active Trials
NCT00152776Completed102Est. Dec 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Colorado TherapeuticsDegarelix
UNION therapeuticsTibolone
Colorado TherapeuticsGnRH antagonist
Colorado TherapeuticsGnRH antagonist
Oregon TherapeuticsEstradiol vaginal ring
TevaArmodafinil
Heidelberg Pharmaovaria comp 10 globuli 3 times per day 24 weeks
Pfizerquinapril
Novo Nordisk1.0 mg estradiol / 0.5 mg norethisterone acetate
Pfizerbazedoxifene 20 mg/ conjugated estrogens 0.45 mg
Novo Nordiskestradiol, 10 mcg
TevaDR-2041a
PfizerDVS-233
Novo Nordiskestradiol, 10 mcg
MSDesmirtazapine

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 1,046,653 patients across 50 trials

Cardiometabolic Consequences of the Loss of Ovarian Function

Start: Jun 2024Est. completion: Aug 2028100 patients
Phase 4Recruiting

the Effects of Different Therapy Regimens on Menopausal Sleep Disorders

Start: Dec 2023Est. completion: Sep 2025180 patients
Phase 4Unknown

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Start: Nov 2021Est. completion: Jul 202555 patients
Phase 4Active Not Recruiting

Bioenergetic Effects of Aging and Menopause (BEAM)

Start: Sep 2019Est. completion: Aug 202457 patients
Phase 4Unknown
NCT03336437Oregon TherapeuticsEstradiol vaginal ring

Estrogen and the Urogenital Microbiome in GSM

Start: Feb 2018Est. completion: Aug 201940 patients
Phase 4Completed
NCT01460628TevaArmodafinil

Effect of Nuvigil on Fatigue

Start: Oct 2011Est. completion: Dec 201325 patients
Phase 4Completed
NCT00152776Heidelberg Pharmaovaria comp 10 globuli 3 times per day 24 weeks

Treating Climacteric Symptoms With a Complex Homeopathic Remedy

Start: Feb 2005Est. completion: Dec 2006102 patients
Phase 4Completed

Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women

Start: Oct 2003Est. completion: May 200570 patients
Phase 4Completed
NCT01705249Novo Nordisk1.0 mg estradiol / 0.5 mg norethisterone acetate

Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

Start: Aug 2001Est. completion: Jun 2003191 patients
Phase 4Completed
NCT00808132Pfizerbazedoxifene 20 mg/ conjugated estrogens 0.45 mg

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Start: Jan 2009Est. completion: Feb 20111,886 patients
Phase 3Completed
NCT00431132Novo Nordiskestradiol, 10 mcg

Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis

Start: Jan 2007Est. completion: Nov 2008336 patients
Phase 3Completed

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Start: Aug 2006Est. completion: Sep 2007622 patients
Phase 3Completed

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Start: Apr 2005Est. completion: Jan 2006465 patients
Phase 3Completed
NCT00108849Novo Nordiskestradiol, 10 mcg

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

Start: Mar 2005Est. completion: May 2007309 patients
Phase 3Completed
NCT00560833MSDesmirtazapine

Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

Start: Oct 2004Est. completion: Jan 2006943 patients
Phase 3Completed
NCT00184795Novo Nordisk0.5 mg estradiol / 0.1 mg norethisterone acetate

Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations

Start: May 2004Est. completion: May 2005576 patients
Phase 3Completed
NCT00560924Novo Nordiskestradiol, 25 mcg

Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women

Start: Mar 2003Est. completion: Mar 20046 patients
Phase 3Terminated

Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

Start: May 2000Est. completion: May 2008394 patients
Phase 3Completed
NCT02184364Boehringer IngelheimLow dose of Klimadynon®

Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints

Start: Nov 1998161 patients
Phase 3Completed
NCT00464971Novo Nordiskestradiol, 25 mcg

Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial

Start: Jan 1995Est. completion: Nov 1996102 patients
Phase 3Completed
NCT00465192Novo Nordiskestradiol, 10 mcg

Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis

Start: Aug 1994Est. completion: Nov 1995230 patients
Phase 3Completed

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Start: Mar 2026Est. completion: Oct 2030200 patients
Phase 2/3Recruiting

Qing'E Formula Therapy on Menopausal Symptoms

Start: Mar 2013Est. completion: Oct 2014240 patients
Phase 2/3Completed

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

Start: Aug 2008Est. completion: Jan 201222 patients
Phase 2/3Completed

PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health

Start: Nov 2023Est. completion: Nov 2024132 patients
Phase 2Unknown

Efficacy Study of Progesterone Tablet in Post-menopausal Women

Start: Jun 2016Est. completion: Apr 201880 patients
Phase 2Completed

Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation

Start: Jun 2019Est. completion: Dec 2021100 patients
Phase 1/2Unknown
NCT04478305PfizerDuavive 0.45Mg-20Mg Tablet

Affect of Duavive on Mood & Anxiety Symptoms

Start: Jul 2024Est. completion: Dec 202530 patients
Phase 1Recruiting

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.

Start: May 2018Est. completion: Jun 202220 patients
Phase 1Unknown

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Start: Dec 2013Est. completion: May 2016100 patients
Phase 1Completed
NCT01085877Novo Nordiskestradiol, 25 mcg

Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis

Start: Mar 2010Est. completion: May 201070 patients
Phase 1Completed
NCT00630435PfizerPremarin®/MPA formulation A

Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation

Start: Feb 2008Est. completion: Jun 200876 patients
Phase 1Completed
NCT01596010Novo Nordisk2 mg estradiol / 1 mg norethisterone acetate

Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women

Start: Oct 2007Est. completion: Nov 200744 patients
Phase 1Completed
NCT00464789PfizerBazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women

Start: Mar 2007Est. completion: May 2007
Phase 1Completed
NCT01486979Novo Nordiskestradiol, 10 mcg

Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis

Start: Jan 2007Est. completion: May 200758 patients
Phase 1Completed
NCT00396799Pfizerbazedoxifene/conjugated estrogens

Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women

Start: Nov 2006Est. completion: Nov 2006
Phase 1Completed
NCT01477632Novo Nordisk0.5 mg estradiol / 0.1 mg norethisterone acetate

Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women

Start: Mar 2005Est. completion: Jun 200524 patients
Phase 1Completed
NCT07136220OtsukaConsumption of soy protein bar

A Pilot Study to Evaluate Equol and Its Effects on Menopausal Symptoms Experienced by Women in Singapore

Start: Jul 2025Est. completion: Dec 2025300 patients
N/ARecruiting

Hot Water Therapy for the Treatment of Menopause-related Hot Flashes

Start: Jan 2025Est. completion: Nov 20250
N/AWithdrawn
NCT06716554BiomedShatavari extract

Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

Start: Oct 2024Est. completion: Jan 202551 patients
N/ARecruiting
NCT06033521PfizerMenopausal hormone therapy Intervention Type: Drug

A Study to Learn More About the Menopausal Hormone Therapies in Korea

Start: Sep 2023Est. completion: Mar 20241,036,294 patients
N/ACompleted

Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

Start: Apr 2021Est. completion: Jul 202140 patients
N/ACompleted

Effects of Pulse Consumption on Bone Health of Postmenopausal Women

Start: Feb 2021Est. completion: Dec 202341 patients
N/ACompleted
NCT04672447BiocorpL-Citrulline

Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function

Start: Jul 2020Est. completion: Apr 202239 patients
N/ACompleted

Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms

Start: Aug 2018Est. completion: Nov 201850 patients
N/ACompleted

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

Start: Dec 2017Est. completion: Sep 202143 patients
N/ACompleted

The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.

Start: Oct 2017Est. completion: Dec 202230 patients
N/ACompleted

A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

Start: May 2017Est. completion: Jun 20201,570 patients
N/ACompleted

Brown Adipose Tissue Activity in Pre- and Postmenopausal Women

Start: Mar 2017Est. completion: May 202369 patients
N/ACompleted
NCT05292261Innovation PharmaceuticalsRecreational team handball

Effects of a Recreational Team Handball-based Programme on Health and Physical Fitness of Postmenopausal Women

Start: Jan 2016Est. completion: Mar 201880 patients
N/ACompleted

Related Jobs in Women's Health

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
5 actively recruiting trials targeting 1,046,653 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.